Methods of modulating tetrabenazine metabolites plasma levels using bupropion
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.
Claims24
A method of treating tardive dyskinesia, comprising administering a therapeutically effective amount of bupropion to a human being daily for at least 8 consecutive days, and wherein the bupropion has an enantiomer excess of at least 90% of S-bupropion.
Dependencies are inferred from the claim text.